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Abstract 
Background: Aspergillus fumigatus is the most prevalent airborne fungal 
pathogen, and the ribotoxin Asp f 1 is one of its major allergens. α-Sarcin is a 
natural variant of Asp f 1 produced by the nonpathogenic fungus Aspergillus 
giganteus. Both proteins show a sequence identity of 87% and almost identical 
3-dimensional structures. α-Sarcin Δ(7-22) is a deletion mutant that displays 
reduced immunoglobulin (Ig) E reactivity and is much less cytotoxic than wild-
type proteins against human transformed cells. 
Objective:  A murine model of sensitization to Asp f 1 was established to test 
the response elicited by this α-sarcin Δ(7-22) deletion mutant. 
Methods: BALB/c mice were treated intraperitoneally with different mixtures of 
recombinant wild-type Asp f 1 and/or a suspension of a commercially available 
A fumigatus standard extract. Mice were then intranasally challenged with 
Asp f 1 or α-sarcin Δ(7-22). Sera were collected for subsequent measurement 
of Ig levels and histological analysis of the nostrils and lungs. 
Results: Sensitization to Asp f 1 was successful only when the purified protein 
was first administered together with the A fumigatus suspension. The model 
was characterized by elevated levels of total IgE in serum and histological 
lesions in the lungs and nostrils. These symptoms were less severe when the 
deletion variant was the protein administered, thus confirming in vivo its lower 
toxic character. 
Conclusions: An easily reproducible mouse model of A fumigatus Asp f 1 
sensitization was established. This model revealed α-sarcin Δ(7-22) to be a 
potential candidate for immunotherapy. 
Key words: Aspergillus. Sarcin. Ribotoxin. Asp f 1. Allergen. Ribonuclease. 
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Resumen 
Antecedentes: Aspergillus fumigatus es el patógeno fúngico aerotransportado 
más abundante, siendo la ribotoxina Asp f 1 uno de sus principales alérgenos. 
La α-sarcina es una variante natural de Asp f 1 producida por el hongo no 
patógeno Aspergillus giganteus. Ambas proteínas muestran una identidad de 
secuencia del 87% y una estructura tridimensional prácticamente idéntica. La α-
sarcina Δ(7-22) es un mutante de deleción mucho menos tóxico que la proteína 
silvestre cuando se ensaya frente a células humanas transformadas y además 
muestra una reactividad reducida frente a IgE. 
Objetivo: El establecimiento de un modelo múrido de sensibilización a Asp f 1 y 
su uso para ensayar la respuesta desencadenada por el mutante de deleción 
α-sarcina Δ(7-22). 
Métodos: Ratones BALB/c fueron tratados intraperitonealmente con diferentes 
mezclas de Asp f 1 recombinante silvestre y/o una suspensión de un extracto 
estándar comercial de A. fumigatus. Los ratones fueron posteriormente 
estimulados intranasalmente con Asp f 1 o α-sarcina Δ(7-22). Posteriormente, 
se recogió suero, que se utilizó para la cuantificación de los niveles de 
inmunoglobulinas, y se realizó un análisis histológico de fosas nasales y 
pulmones. 
Resultados: La sensibilización a Asp f 1 sólo tuvo éxito cuando la proteína pura 
se suministró simultáneamente con la suspensión de A. fumigatus. El modelo 
se caracterizó por sus elevados niveles de IgE en suero así como por lesiones 
histológicas en pulmones y fosas nasales. Estos síntomas fueron menos 
graves cuando se administró la variante de deleción lo que confirmó in vivo su 
carácter menos citotóxico. 
Conclusiones: Se ha establecido un modelo múrido fácilmente reproducible de 
sensibilización al alérgeno Asp f 1 de A. fumigatus. Este modelo es coherente 
con que la α-sarcina Δ(7-22) sea un potencial candidato para estudios de 
inmunoterapia. 
Palabras clave: Aspergillus. Sarcina. Ribotoxina. Asp f 1. Alérgeno. 
Ribonucleasa. 
 5 
 
5 
Introduction 
Aspergillus fumigatus is exceptional in that it is both a primary and 
opportunistic pathogen as well as an important source of allergens [1]. Its 
ubiquitous spores are continuously inhaled by humans, with the result that 
exposure of the respiratory tract is almost constant. Inhalation very rarely 
causes adverse effects, as the conidia are usually eliminated efficiently by the 
innate immune system. More widespread use of immunosuppressive therapy is 
leading to increasingly frequent conditions involving infection by A fumigatus. 
This microorganism is one of the most prevalent airborne fungal pathogens [2] 
and the etiological agent in 80% of Aspergillus-related diseases, including 
hypersensitivity, pneumonitis, allergic rhinitis, immunoglobulin (Ig) E–mediated 
asthma, severe allergic bronchopulmonary aspergillosis (ABPA), and different 
invasive infections in immunocompromised patients [1,3]. 
 The ribotoxin Asp f 1 is one of the major allergens of A fumigatus, with a 
prevalence of more than 80% in patients with ABPA [1,4-6]. α-Sarcin, a natural 
variant of the nonpathogenic Aspergillus giganteus, is the best-characterized 
member of this ribotoxin family, a group of fungal and highly specific secreted 
ribonucleases [7]. Asp f 1 shows 87% amino acid sequence identity with α-
sarcin [4] and an almost identical 3-dimensional structure [6,8,9]. Both proteins 
are so similar in enzymatic and structural terms that the only factor preventing A 
giganteus from being infectious is considered to be its inability to grow above 
30ºC. The toxicity of ribotoxins comes from their ability to reach the cytosol via 
receptor-independent endocytosis [10]. Once inside the host cell, ribotoxins 
inhibit protein biosynthesis by inactivating the ribosomes, thus causing cell 
death [7]. The NH2-terminal β-hairpin has been shown to play a key role both in 
the cytotoxic effect of ribotoxins and in IgE–mediated responses [6,11]. In fact, 
the deletion mutant α-sarcin Δ(7-22), from which this β-hairpin is eliminated 
[11], shows much lower cytotoxicity against human rhabdomyosarcoma cells in 
culture and a 50% reduction in human IgE reactivity. Interestingly, α-sarcin Δ(7-
22) maintains the wild-type 3-dimensional structure [12] and its prevalence in 
sera from patients with ABPA [6]. These results indicate that α-sarcin Δ(7-22) is 
a hypoallergenic variant of Asp f 1. 
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Immunotherapy against A fumigatus allergy is based on allergenic 
extracts that are difficult to standardize because they contain up to 200 different 
molecules [13]. In addition, the risk of anaphylactic side effects during treatment 
cannot be ruled out. The use of recombinant allergens with reduced IgE-binding 
capacity [14-16] could help resolve these drawbacks, and, in this regard, the 
deletion variant of the ribotoxins described above is a promising molecule for 
immunomodulating therapies. In the present study, we attempt to establish an 
easily reproducible murine model of sensitization to Asp f 1 and use it to 
compare the response elicited by this deletion variant with that of the wild-type 
protein.
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Materials and methods 
Mice 
Female, 6- to 8-week-old BALB/c mice (Harlan Interfauna Ibérica SA, 
Barcelona, Spain) were maintained at the Animal Care Services of the Faculty 
of Biology (Universidad Complutense, Madrid, Spain) according to the local 
guidelines for animal care. The study was approved by the Animal 
Experimentation Ethics Committee of our institution. 
 
Protein Production and Purification 
Escherichia coli BL21 (DE3) cells cotransformed with a thioredoxin-
producing plasmid (pT-Trx) and the corresponding Asp f 1 or the deletion 
mutant α-sarcin Δ(7-22) plasmids were used to produce the proteins, as 
previously described [6,11]. Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) of proteins, protein hydrolysis, amino acid 
analysis, and circular dichroism spectra were performed according to standard 
procedures [5,17-20]. Western blots were performed as described elsewhere [6] 
using rabbit sera raised against wild-type α-sarcin or Asp f 1. Homogeneity of 
the protein samples was assessed using the procedures described above. 
 
Preparation of Aspergillus fumigatus Suspension  
A standard commercially available mixture of spores and mycelia 
inactivated by gamma radiation (Allergon AB, Ängelholm, Sweden) was 
resuspended in phosphate-buffered saline (PBS) at 1 mg/mL (w/v) and shaken 
for 2 hours at 250 rpm and 4ºC. This suspension is referred to as the Af 
suspension throughout the text. 
 
Sensitization and Challenge 
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Different approaches were tried in order to establish a murine model of 
sensitization to recombinant Asp f 1. The success of each protocol was 
evaluated by measuring total and specific antibody levels, including IgE, IgG1 
and IgG2a (see below), as well as by assessing clinical manifestations such as 
histopathological alterations, pilar erecti, and weight loss. Finally, the successful 
procedure was as follows: Mice (n=5) were sensitized by 2 intraperitoneal 
injections with 1 µg of Asp f 1 and 10 µL of the Af suspension adsorbed to 2 mg 
of Al(OH)3 in 150 µL of PBS at 7 day-intervals. After 7 days mice were 
challenged by intranasal administration of different amounts of Asp f 1 or the 
mutant α-sarcin Δ(7-22) in 50 μL of PBS on 3 consecutive days under mild 
anesthesia with ketomine/xylazine (Figure 1). With the mouse supine, the 
antigen solution was injected into the nostrils using a micropipette. The animal 
was restrained in this position for a minimum of 10 minutes until it awoke from 
the anesthesia. Six different groups were studied. Group A were not treated, 
and were used as controls, whereas group B mice received the intraperitoneal 
mixture but were intranasally challenged with PBS only. Groups C, D, and E 
were intranasally challenged with 1, 5, and 10 µg of purified Asp f 1, 
respectively. Group F were challenged with 1 µg of α-sarcin Δ(7-22). Seven 
days after the last intranasal challenge, blood samples were collected from the 
retro-orbital plexus (terminal bleeding) and tissues were removed for 
histological examination. 
 
Determination of Specific IgG1, IgG2a, and Total IgE in Serum 
Antibody (Ab) binding was measured by an enzyme-linked 
immunosorbent assay (ELISA) as previously described [21]. In order to 
quantitate Asp f 1 specific antibodies, serum samples were diluted 1:25 000 for 
IgG1, 1:400 for IgG2a, and 1:5 for IgE. Antibody levels were expressed as 
optical density (OD) values read at 492 nm. Total IgE (diluted 1:40) levels in 
serum were measured by sandwich ELISA using the OptEIA mouse IgE set 
(PharMingen, San Diego, CA, USA) according to the manufacturer’s 
instructions.  
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Histopathology 
Nostril and lung samples were fixed in 10% buffered formalin, routinely 
processed, and paraffin-embedded. Sections (3 µm) were stained with 
hematoxylin-eosin to examine general morphology and cellular infiltration, and 
the periodic acid-Schiff (PAS) technique was applied to observe mucus 
production. Sections were examined under a light microscope by a pathologist 
who was blinded to the protocol design. The intensity and severity of lung and 
nostril involvement were assessed on a semiquantitative score ranging from 0 
to 4, with the respective values corresponding to negative, faint, weak, 
moderate, or severe lesions.
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Results 
Sensitization Protocol 
 Intraperitoneal immunization with purified Asp f 1 only was insufficient to 
induce a response, even when administered in amounts as high as 10 µg. 
Given that allergy to A fumigatus usually occurs alongside fungal infection, a 
second approach was tried using the Af suspension as the only protein source 
to achieve sensitization. Once again, antibody levels remained unaffected and 
toxic effects were not observed. This result was consistent with the absence of 
Asp f 1 in the Af suspension as revealed by immunoblotting. Consequently, in 
the third approach, purified Asp f 1 and the Af suspension were combined in the 
hope that the latter would contain some component that would lead to an 
allergic response, as described elsewhere [22]. 
 Thus, the final successful strategy was based on the intraperitoneal 
administration of a mixture containing both the Af suspension (10 µl) and the 
recombinant protein (1 µg) in Al(OH)2, followed by three intranasal challenges 
with different doses of recombinant Asp f 1 only. Mice challenged with 10 µg of 
Asp f 1 systematically died after the third intranasal challenge (Figure 1). 
Therefore, group E was not further studied. The groups treated with 1 or 5 µg 
did experience adverse effects, as evidenced by weight loss and pilar erecti, but 
fully recovered once the Asp f 1 challenge was interrupted. These results 
suggest the existence of a dose-dependent and more complex toxic effect. 
 
Antibody Response 
Intraperitoneal injection of the Asp f 1–Af suspension combination was 
sufficient to induce a 7-fold increase in total IgE serum levels when compared to 
controls (Figure 2). This response was further strengthened after intranasal 
challenge with 5 μg of Asp f 1 (Figure 2). No significant differences were 
observed when mice were challenged with lower amounts of protein. Asp f 1–
specific IgE, IgG1, or IgG2 antibodies were not detected in the sera of any of 
the immunized mice within the limits of ELISA and Western blot analysis. 
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Lung and Nostril Histology 
Lung tissue was obtained from each experimental group, except for 
group E, 7 days after the last intranasal challenge to assess the effect of the 
sensitization protocol on airway inflammation. Histologic analysis revealed that 
Asp f 1 challenge promoted severe perivascular and peribronchial infiltrations of 
inflammatory cells—lymphocytes, neutrophils and occasional eosinophils and 
macrophages—in all lobes of the lungs. These effects were even more evident 
in mice challenged intranasally with 5 µg of protein, in which marked re-
epithelialization and fibrosis, characterized by enrichment of collagen fibers, 
were also observed throughout the parenchyma (Figure 3).  
 Examination of nostril tissue revealed that it was also affected by Asp f 1 
sensitization (Figure 4). A mixed infiltrate of cells, especially lymphocytes and 
neutrophils, was observed in the nostrils of the experimental animals. Again, the 
most severe effects were obtained for the higher Asp f 1 dose. Mucus 
hypersecretion in the nostrils was a notable histopathologic feature of the 
Asp f 1–challenged mice.  
 
Effect of a Deletion Mutant With Diminished IgE Response 
The Δ(7-22) deletion mutant of α-sarcin was also studied to evaluate its 
effect on the onset of sensitization. Thus, group F mice were intranasally 
challenged with 1 µg of Δ(7-22) α-sarcin, that is, the amount of recombinant 
Asp f 1 used for group C mice. No significant effects on total IgE levels were 
observed in the mutant-challenged mice compared with group C mice (Figure 
2). Nevertheless, intranasal administration of the mutant resulted in diminished 
perivascular and peribronchial cellular infiltration and inhibited epithelial cell 
hyperplasia in the lungs (Figure 3). With respect to the nostrils, the use of the 
mutant induced a similar cellular inflammatory response, although mucus 
release was notably diminished (Figure 4).
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Discussion 
One of the most promising alternatives to conventional immunotherapy for 
allergy is the use of hypoallergenic derivatives as vaccines [16,23]. However, 
before clinical application, in vitro and in vivo evaluation of these presumed 
hypoallergens is required to identify the best candidates. We established a 
murine model of sensitization to Asp f 1 in order to test the safety and in vivo 
suitability of a variant of Asp f 1, the α-sarcin Δ(7-22) mutant, as an 
immunotherapeutic agent for allergy. 
 Most animal models of A fumigatus sensitization have been achieved in 
mice by intranasal administration of crude extracts of the fungus or of intact 
organisms, particularly the conidia [22,24,25]. We were not able to sensitize 
mice to the commercially available extract used in this study. This could be due 
to nondetectable levels of Asp f 1, the heterogeneity and lack of reproducibility 
of the extracts used by other authors, or both. In fact, intraperitoneal 
administration of purified Asp f 1 alone also rendered healthy animals with 
undetectable levels of total IgE. However, when BALB/c mice were sensitized 
by intraperitoneal administration of a combination of Asp f 1 and Af suspension 
in Al(OH)3 followed by intranasal challenge, onset of an allergic-like state was 
observed in the high levels of total IgE in serum and histological lesions in the 
lung and nostrils. However, Asp f 1–specific IgE, IgG1, IgG2a antibodies were 
not detected, in agreement with previous studies of other authors [26] who 
observed that immunization of animals with an A fumigatus extract induced an 
increased level of total serum IgE, but not specific IgE or IgG antibodies. 
 Therefore, the advantage of this model over others described elsewhere 
[25-29] is its reproducibility, which is based on the use of a widely available 
extract and a purified and well-characterized recombinant protein. The other 
procedures presented above were based on poorly described homemade 
extracts or allergen-enriched mixtures. 
In our model, lung lesions typically consisted of perivascular and 
peribronchial infiltrates of inflammatory cells, emigration of some eosinophils 
into the lumen, and, in severe cases, epithelial hyperplasia. Accumulation of 
collagen was frequent in the parenchyma, and this effect of fibrosis was much 
 13 
 
13 
more severe in group D mice. In addition, the strong inflammation in the lungs 
induced by A fumigatus antigens persisted over 7 days after the last intranasal 
challenge. Similar results have been reported by other groups [27-29]. In the 
present analysis, the histological study was further extended to the nostrils and 
the results obtained were also compatible with the induction of an allergic 
response to A fumigatus antigens. 
Thus, this model of A fumigatus sensitization is not only easy to 
reproduce but also suitable for the in vivo testing of its wild-type and mutant 
allergens. Overall, however, the results suggest that the allergic-like phenotype 
observed in the present model is due not only to the typical IgE-dependent 
response, but also to the result of a much more complex interaction between 
the host immune system and A fumigatus antigens, including ribotoxins. The 
results suggest that the allergic state induced by the combination of Asp f 1 and 
Af suspension could result from the cumulative toxic effects of several toxins, 
esterases, and proteases present in the extract. These could also act as 
adjuvants, perhaps by inducing epithelial damage and allowing normal antigens 
to bypass the mucosal barrier [22,30,31]. Thus, the specific roles of the 
individual allergens have yet to be determined. In addition, it has been shown 
that proteases preferentially induce TH2 responses, suggesting that they could 
be skewing the response to A fumigatus antigens to a more allergic phenotype 
[32,33]. 
 Challenge with the α-sarcin Δ(7-22) mutant resulted in a substantial 
decrease in lung and nostril lesions when compared to those induced by wild-
type Asp f 1, although total IgE levels remained unaffected. These data confirm 
the low toxic character suggested previously for the deletion mutant in mice [6]. 
Toxicity at higher doses cannot be ruled out and warrants further investigation.  
 In summary, we established an easily reproducible mouse model of A 
fumigatus sensitization. Despite its limitations, this in vivo model is a suitable 
system for preclinical testing of recombinant allergens and their derivatives. The 
decreased toxicity induced by α-sarcin Δ(7-22), in terms of a reduced 
inflammatory response in the airway and lower human IgE binding activity, 
confirms this molecule as a suitable candidate for immunotherapy.
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Figure 1. A, Experimental protocol. Mice were sensitized by intraperitoneal 
injection of a mixture containing Asp f 1 (1 µg) and the Af suspension (10 µL) on 
Al(OH)3, followed by intranasal challenge with Asp f 1 (1, 5, or 10 µg; groups C, 
D, and E, respectively) or α-sarcin Δ(7-22) (1 µg; group F) on 3 consecutive 
days. After 1 week, blood and tissue samples were collected. B, Survival of 
mice treated according to these protocols expressed as the percentage of mice 
surviving as a function of time of treatment. Group A comprised nontreated 
control mice. Group B mice underwent the intraperitoneal challenge but 
received intranasal phosphate-buffered saline only. IN indicates intranasal; IP, 
intraperitoneal. 
 
Figure 2. Total serum immunoglobulin E levels in the different groups of 
sensitized mice determined by enzyme-linked immunosorbent assay. Bars 
represent group mean (SEM) of 5 mice per group. 
 
Figure 3. A-F, Representative photomicrograph (hematoxylin-eosin) of lung 
section from mice in groups A, B, C, D, and F. Histologic analysis revealed 
numerous zones of inflammation (white arrows) and epithelial hyperplasia 
(black arrows) in lungs from group C and D animals compared with control mice 
(groups A and B). Fibrosis was especially noteworthy in group D (see the inset 
photomicrograph in panel D). G, Histological score for lung inflammation. Data 
are expressed as the mean (SEM) of 5 mice per group. B indicates bronchium; 
V, blood vessel. 
 
Figure 4. A-F, Representative photomicrograph (hematoxylin-eosin) of nostrils 
section from mice in groups A, B, C, D, and F showing cellular infiltration. The 
insets are photomicrograph periodic acid-Schiff stains of a wider field where the 
mucus plugs are marked with asterisks. G, Histological score of inflammation 
and mucus secretion. Data are expressed as the mean (SEM) of 5 mice per 
group. 
 




